It was more than 20 years ago that patients with systemic lupus erythematosus (SLE) were first reported to display elevated serum levels of type I interferon (IFN). Since then, extensive studies revealed a crucial role for type I IFN in SLE pathogenesis. The current model proposes that small increase of type I IFN production by plasmacytoid dendritic cells (pDCs) is sufficient to induce unabated activation of immature peripheral DCs. IFN-matured DCs select and activate autoreactive T cells and B cells, rather than deleting them, resulting in peripheral tolerance breakdown, a characteristic feature of SLE. Furthermore, immune complexes provide an amplification loop to pDCs for further IFN production. In the past 5 years, high-throughput technologies such as expression profiling and single-nucleotide polymorphism (SNP) typing established the role of altered type I IFN system in SLE, and a detailed picture of its molecular mechanisms is beginning to emerge. In this review, we discuss two major lines of genetics studies on type I IFN pathway related to human SLE: (1) expression profiling of IFN-responsive genes and (2) disease-associated SNPs of IFN-related genes, especially IRF5 (IFN-regulatory factor 5). Lastly, we discuss how such genetic alterations in type I IFN pathway fit in the current model of SLE pathogenesis.
Introduction/historical perspective
Systemic lupus erythematosus (SLE) is a chronic, inflammatory autoimmune disease that affects multiple organs and is characterized by production of autoantibodies to nuclear antigens (for example, histones, ssDNA, dsDNA, Ro, La) and immune complex (IC) formation. SLE is a complex disease that involves multiple, interacting genetic and environmental factors, the identification of which is a challenging task. To date, only limited success has been achieved.
Data linking type I interferon (IFN) to SLE were presented as early as 1979, when Hooks et al. 1 first observed elevated levels of IFN in SLE sera. Since then, multiple literatures have supported this observation. [2] [3] [4] In the later years, role of type I IFN in SLE was more clearly implicated by a series of studies in humans who received IFNa as a therapeutic agent for viral hepatitis or carcinoid tumors. Nearly a quarter of IFNa-treated subjects (22%) developed a positive blood test for antinuclear antibodies, and one in five (19%) developed various symptoms of autoimmunity, including a small number of cases with SLE (0.7%). 5, 6 Another study reported that some patients treated with IFNa developed other immune syndromes such as type I diabetes, psoriasis, inflammatory arthritis and Sjö gren syndrome, 7 which may share genetic background with SLE. 8, 9 Conclusive evidence for a crucial role for IFN in SLE pathogenesis has been provided over the past 5 years, with the help of remarkable progress in comprehensive gene-hunting technologies, such as microarray and highthroughput SNP (single-nucleotide polymorphism) typing. Using gene expression microarray, we have filed a list of IFN-regulated mRNA transcripts that are expressed at elevated levels in the blood cells of SLE patients. [10] [11] [12] Furthermore, protein microarray experiments revealed IFN-inducible protein expression profile in serum from SLE patients. 13 High-throughput SNP typing platforms such as Illumina (Illumina Inc., San Diego, CA, USA) and Sequenom (Sequenom Inc., San Diego, CA, USA) enabled us to carry out B0.5 million genotypes a day with high fidelity. Together with a great effort in the recruitment of DNA samples from patients and controls, an increasing number of large-scale genetic association studies are being carried out. These recent advances in science and technology have led us to understand better the role of type I IFN system in SLE.
Type I IFN in human SLE
Type I IFNs were first identified as a cytokine to enhance mammalian antiviral resistance.
14 Viral infection rapidly induces leukocyte production of IFNa and IFNb, which have a central role in host defense by triggering inflammatory and antiviral responses. They also influence cell proliferation, differentiation and survival of mature lymphocytes, class switching at immunoglobulin heavy chain loci, and activation of dendritic cells (DCs). 15 Type I IFN genes cluster at human chromosome 9p22. There are at least 13 IFNa genes, as well as IFNb, IFNk, IFNt and IFNo, together comprising the type I IFNs. 16 All type I IFN family members bind to common receptor complexes, IFNAR1 and IFNAR2, and initiate a JAK/ STAT signaling cascade leading to the transcription of specific IFN-inducible genes. 17 What causes elevated type I IFN expression observed in SLE? A strong candidate is IC. SLE patients have been shown to exhibit increased levels of apoptosis as well as decreased clearance of apoptotic cell fragments, such as DNA and RNA, from plasma. [18] [19] [20] Such endogenous immunostimulatory chromatin can drive autoantibody production and lead to generation of chromatin-containing ICs. Ronnblom et al. [21] [22] [23] [24] [25] [26] have investigated the capacity of ICs in SLE sera to trigger IFNa production by plasmacytoid dendritic cells (pDCs), which is the primary source of type I IFNs. They provided evidence that autoantibodies associated with apoptotic DNA and RNA, particularly single-stranded CpG sequences in genomic DNA, can provide a stimulus that results in IFNa secretion. They also showed that internalization of the ICs by Fcg receptor II, but not FcgRI or FcgRIII, is required for most effective activation of IFNa production by pDCs. 27 Secondly, a virus could be an exogenous trigger for IFN pathway activation in SLE. After virus infection, unabated activation of IFN pathway, possibly caused by gene polymorphisms, can lead to differentiation of autoreactive B cells into antibody-secreting plasma cells. 28 The antibodies cause amplification of chromatincontaining IC formation and may result in elevated type I IFN production.
Toll-like receptor (TLR) is a key molecule in type I IFN signaling and has been a matter of interest for SLE researchers since its discovery in 1997. 29 To date, 10 members of human TLRs have been identified. TLRs recognize specific endogenous and exogenous microbial ligands such as genomic DNA, single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), lipopolysaccharide (LPS), flagellar proteins, lipopeptides and trigger activation of type I IFN pathway, which result in the eradication of invading pathogens. 30, 31 Among the TLR family, those that are expressed on pDCs (also known as interferon-producing cells) and trigger cell activation by DNA, ssRNA or dsRNA are attractive candidates for transducers of the elevated type I IFN signals in SLE. Human pDCs predominantly express TLR6, TLR7 and TLR9; [32] [33] [34] however, TLR6 does not induce IFNa/b. 30, 32 Therefore, TLR 7/8 (TLR8 is phylogenetically close to TLR7) that recognizes ssRNA 35 and TLR9 that recognizes CpG DNA, 36 are most relevant players in pDCs. In fact, mouse studies showed that single-stranded CpG sequences bind to toll-like receptor 9 (TLR9) expressed on B cells and DCs and cause activation and secretion of various cytokines including type I IFNs. 36, 37 TLR3 is another member of the TLR family that recognizes chromatin. It is stimulated by dsRNA and expressed in B and T cells but not in pDCs, 38 and therefore, may have an important role in activation of autoreactive T and B cells, together with TLR7/8/9 that are also expressed on B cells.
Type I IFN in mouse lupus models
In New Zealand black (NZB) X New Zealand white (NZW) F1 female mice, polyinosinic polycytidylic acid (poly I:C), a surrogate for dsRNA, accelerates the development of lupus. 39 Its parental strain NZB also expresses lupus-like disease. Deletion of the IFNa/b receptor in NZB mice shows abrogation of a number of immune system alterations including autoantibody production. [40] [41] [42] Fas-defective MRL/lpr is another established lupus model. 43 Injection of poly I:C in B6 lpr mice resulted in increased severity of renal disease, higher titers of autoantibodies, increase in serum Ig and accumulation of activated lymphocytes. In addition, introduction of homozygous mutation for type I IFN receptor resulted in dramatic decrease of ICs' deposition in the kidney and reduced lymphadenopathy. 41 These observations support the importance of type I IFN and are compatible with our understanding on human SLE. However, significant differences are also known between human SLE and mouse lupus models. In murine lupus, importance of IFNg, a type II IFN, has been more highlighted, particularly at the site of lymphocyte and inflammatory cell infiltration in the kidney. [43] [44] [45] On the other hand, in humans, peripheral blood expression profile appears to be preferentially induced by IFNa, but not by IFNg, 12, 46 although a role of IFNg as an inducer of organ damage cannot be excluded.
Data from murine lupus models have also supported a genetic contribution of IFN-regulated genes to lupus susceptibility. IFN-inducible protein 202 gene (ifi202) at the Nba2 locus on chromosome 1 is expressed at high levels in NZB mice because of promoter region polymorphisms. 47 IFI202 is a transcription factor that influences proliferation, survival and differentiation of B cells and induced by both IFNa and IFNg. 48 Such an example indicates the need to investigate human IFN-inducible genes as well as genes in its signaling pathway as candidates for susceptibility genes to human SLE.
Expression profiling of IFN-responsive genes in SLE
Although reliable quantification of type I IFN-related gene products in SLE patients has been challenging both at mRNA and protein levels, several groups have succeeded in providing a sensitive and relatively quantitative measure using microarray technology. Comprehensive profiling of gene expression in peripheral blood mononuclear cells (PBMCs) and protein expression in sera from patients has consistently shown the upregulation of IFN-inducible genes in SLE compared with normal controls. 10, 11, 13, [49] [50] [51] [52] IFN signature in PBMCs Baechler et al. 10 studied gene expression microarray profiles in 48 SLE patients and 42 controls to identify pathways that might be dysregulated in PBMCs of SLE patients. Several immune-related genes were up-regulated in the SLE patients including Fc receptor for IgA (FCAR, CD89), Fc receptor for IgG such as FcgRIIA (CD32) and FcgRI (CD64), TNFRSF6 (Fas/CD95), and three molecules in the inflammatory IL-1 cytokine pathway: IL-1b, IL-1 receptor II (IL-1RII) and IL-1 receptor antagonist. Notably, genes in the cluster of type I IFN pathways (referred to as 'IFN signature') were upregulated in over half the patients (referred to 'IFNhigh'), whereas the others showed comparable levels to the majority of controls (IFN-low). Most of the control subjects expressed low levels of IFN signature genes.
In order to determine which genes in this cluster could be regulated by IFN treatment in vitro, PBMCs were isolated from four healthy donors and cultured for 6 h after stimulation with IFNa/b or IFNg. Overall, 23 of the 161 genes that distinguish lupus patients from healthy controls, were found to be IFN regulated, 10 and 22 IFN signature genes were strikingly upregulated in 'IFNhigh' SLE patients. 53 Among these, at least nine genes (LY6E, OASL, IFIT1, IFIT4, STAT1, MX1, MX2, PLSCR1 and IRF7) were replicated by other independently carried out microarray studies. 11, [49] [50] [51] Baechler and co-workers 10,53 also examined whether there was any clinical feature that distinguishes 'IFNhigh' group of patients from 'IFN-low group'. The frequency of SLE who have a manifestation of renal disease, central nervous system lupus and hematological deficit (particularly leukopenia, lymphopenia and thrombocytopenia) was significantly higher in the 'IFNhigh' group of patients as compared to the 'IFN-low', suggesting that IFN signature can be a marker for patients with severe SLE.
IFN signature in serum protein
Inspired by the transcriptome analyses, Bauer et al. 13 examined the levels of 160 serum proteins in 15 IFNhigh, 15 IFN-low SLE patients and 15 healthy controls using a high-throughput protein microarray technology, Luminex. Luminex assays are based on custom dualantibody sandwich immunoassay arrays using xMAP technology (multi-analyte profiling beads) enabling the detection and quantification of multiple protein targets simultaneously. 54, 55 Of the 160 analytes measured, 30 showed significant differences between the 'IFN-high' SLE group and controls. The extent of expression level difference was bigger in 'IFN-high' SLE than in 'IFN-low SLE'; however, only 11 of 30 analytes were significantly different between 'IFN-high' and 'IFN-low' SLE. Notably, 12 chemokines were included in the upregulated analytes (CCL2, CCL3, CCL7, CCL8, CCL17, CCL19, CXCL2, CXCL8, CXCL9, CXCL10, CXCL11 and CXCL13). Most of these chemokines (9/12) were transcriptionally inducible by type I IFN in PBMC. In addition to IFN gene score used for defining 'IFNhigh'/'low', 10 correlation between chemokine levels and various clinical measures/features of disease activity was shown. For example, many of the IFN-regulated analytes showed strong positive association with the SLEDAI 56 and the SLAM-R, 57 two commonly used measures of global disease activity. CXCL11 (I-TAC), CXCL13 (BLC), CXCL10 (IP-10) and CCL3 (MIP-1A) were observed at significantly high levels in serum of patients with renal disease. These data suggested that the levels of serum chemokines might serve as convenient biomarkers for disease activity in SLE.
Authors finally hypothesized that high levels of systemic chemokines in active SLE, driven by type I IFN, lead to a state of 'chemokine confusion' that alters the normal trafficking and chemotaxis of leukocytes in the body, contributing to the widespread inflammatory immune responses observed in SLE.
SLE-associated variations in IFN pathway genes
It is not clear whether the type I IFN signature is a result of a dysregulated immune system or rather it reflects genetic variation that is causally involved in the pathogenesis of human SLE. In addition to the wellestablished pathogenic role of genetic variation in major histocompatibility complex, a number of rare and common variants, such as SNP, deletion/insertion and copy number variations are known to be important for disease pathogenesis. To identify such genetic variations, one of the conventional ways is to target genes in cellsignaling pathways involved in a range of immunological events. So far, several SLE-related gene polymorphisms are discovered in immune-signaling pathways, such as PDCD1 (PD-1) in the RUNX pathway, 58 PTPN22 (protein tyrosine phosphatase N22) in the T cell-signaling pathway, 8 Fcg receptor II and III in immunoglobulindependent cell-signaling pathway [59] [60] [61] [62] and CR2 in complement pathway. 63 Recently, Sigurdsson et al. 64 analyzed 44 SNPs in 13 genes from the type I IFN pathway in 679 Swedish, Finnish and Icelandic patients with SLE, in 798 unaffected family members and in 438 unrelated control individuals for joint linkage and association with SLE. They identified association in TYK2 (tyrosine kinase 2) and IRF5 (IFN-regulatory factor 5) with adjusted P values of 1.1 Â 10
À5
for TYK2 rs2304256 SNP and 7.9 Â 10 À6 for IRF5 rs2004640 SNP. TYK2 binds to the type I IFN receptor complex with JAK1 and initiate a JAK/STAT signaling cascade leading to the transcription of IFN signature genes. 65 IRF5 is a member of IRF family that plays an important role at downstream of the TLRMyD88 signaling pathway as a master transcription factor leading to the transcription of genes for inflammatory cytokines as well as IFNa and IFNb. 66, 67 These findings were the first evidence that gave us an idea that type I IFN signature was, at least in part, controlled by gene polymorphisms and was causally involved in SLE pathogenesis, rather than just a feature of disease phenotype.
IRF5
The human IRF family comprises nine members from IRF1 through IRF9. Each IRF contains a conserved DNAbinding domain that contains a helix-turn-helix motif of approximately 120 amino acids. This region recognizes a consensus DNA sequence known as the IFN-stimulated response element called ISRE (GAAANNGAAA[G/C] [T/C]), which was initially known as the IRF enhancer (IRF-E). ISREs are found in the promoters of various IFN signature genes such as IFNa, IFNb, IL-12, CXCL10 and IFIT1. 68 Expression of IRF5 was detected in B cells and DCs 69 and further enhanced by activation of type I IFN pathway because promoter of IRF5 itself also possesses ISRE. 70 Among the IRF family members, IRF5 and IRF7 are known to share the same signaling pathway that is initiated through TLR7/8 and TLR9. Unlike other TLRs that are expressed on cell surface, TLR7/8 and TLR9 are expressed in endosome and stimulated by internalized ssRNA and dsDNA, respectively. 66 Efficient stimulation of TLR7/8/9 requires engagement of FcgRII or FcgRIII, carries of ICs from cell surface to endosomal compartment. 27, [71] [72] [73] IRF5 is a cytoplasmic protein anchored on endosome by binding to MyD88. After ligation of TLR7/8/9 with specific chromatin ligands, the MyD88-bound IRF5 is activated by TRAF6 by an as-yet-unknown mechanism. Activated IRF5 dimerizes and translocates to the nucleus led by NLS (nuclear localization signal), where it binds to ISRE in the promoter sequences and activates transcription of IFNa/b and pro-inflammatory cytokines such as TNFa, IL-12 and IL-6, probably in cooperation with NFkB. 66, 74 Another IRF family member IRF4 also binds to MyD88 at an overlapping region with IRF5-binding site, thereby serving as an antagonist of IRF5 by inhibiting the binding of IRF5 to MyD88 and attenuating the TLR-MyD88 signaling. 66, 75 Barnes et al. 76 carefully examined the function of IRF5 by in vitro experiments using human cell lines. They showed that IRF5-mediated activation is virus specific. Infection by Newcastle disease virus (NDV), vesicular stomatitis virus (VSV) and herpes simplex virus type I (HSV-1), but not Sendai virus, can activate IRF5, leading to induction of IFNa. Knockdown of IRF5 by siRNA in 2fTGH human fibroblast cell line reduces type I IFN induction in response to TLR7 ligand. 77 IRF5 competes with IRF7 in the formation of homodimers, and IRF5/ IRF7 heterodimers result in a repression rather than enhancement of IFNa transcription. 78 By means of microarray experiments in BJAB human B cell lines, they demonstrated that 657 genes (568 upregulated and 89 downregulated) were modulated by IRF5 by at least twofold. 79 These genes are considered to be either upregulated by direct binding of IRF5 to its promoter or secondarily upregulated by type I IFN, produced by IRF5 activation.
IRF5 in murine lupus
In addition to recent reports on human SLE, insights from mouse studies also support the importance of gene polymorphisms in TLR-MyD88 signaling pathway in lupus pathogenesis. FcgRIIBÀ/À mice with B6 background develop spontaneous SLE-like disease, characterized by the production of autoantibodies and development of glomerulonephritis. Addition of the Yaa modifier to the FcgRIIB-deficient mice increases severity of disease. 80, 81 Yaa was first identified on Y chromosome derived from the SB/Le strain as an autoimmune accelerator; 82 however, what elements of Yaa genome are responsible for severe lupus had not been known. Recently, Pisitkun et al. 83 and Sabramanian et al. 84 demonstrated that genomic duplication of X chromosomal region encompassing TLR7 gene locus onto Y chromosome accounts for Yaa mutation. Thus, male mice carrying Yaa express double dose of TLR7 gene, one from original X and another from duplicated Y chromosome, which leads to enhanced TLR7-signaling pathway. This finding represents an excellent example in which gene copy number variation plays an important role in disease pathogenesis, although the contribution of the duplicated gene other than TLR7 requires further investigation.
The mice deficient for IRF5 gene (Irf5À/À mice) were initially reported to show severely impaired production of pro-inflammatory cytokines in pDCs when stimulated by various TLR ligands; however, IFNa induction was normal. 85 However, a recent report from the same investigators showed that production of IFNa and IFNb in splenic macrophages as well as serum IFN levels in response to viral infections were markedly decreased in Irf5À/À mice, supporting the role of IRF5 in type I IFN production also in mice, although the contribution might be stimulation specific and cell type dependent. 86 Association of IRF5 gene polymorphisms with SLE Association of IRF5 intron 1 SNP with SLE In an effort to replicate the association of IRF5 rs2004640T with SLE, 64 Graham et al. 87 genotyped four sets of SLE cases and controls from the United States, Spain, Sweden and Argentina (total of 1661 cases and 2508 controls) as well as 470 families with SLE. They found a significant increase of the T-allele frequency in the patients; overall, four-cohort analysis showed 60.4% in cases versus 51.5% in controls (P ¼ 4.4 Â 10
À16
). In 470 SLE pedigrees, T allele showed significant overtransmission using the transmission disequilibrium test (219:153 T:U, P ¼ 0.0006). 87 When these data were combined with the previously published data from Swedish and Finnish cohorts, 64 a robust and consistent association of the rs2004640T allele with SLE was observed. Overall odds ratios (OR) showed 1.47 (95% confidence interval: 1.36-1.60), with P ¼ 4.2 Â 10 À21 . The individuals carrying two copies of rs2004640T allele were at higher risk for SLE (OR ¼ 2.01, P ¼ 3.7 Â 10 À14 ) than individuals carrying one copy (OR ¼ 1.27, P ¼ 0.0031), suggesting a dosage effect of this allele. 87 Graham et al. next investigated the potential function of the rs2004640T allele. As shown in Figure 1 , rs2004640T allele is located 2 bp downstream of the intron-exon border of exon 1B, creating a consensus GT donor site for alternative splicing. The splicing of IRF5 is known to be highly complex. 70 Transcription of multiple IRF5 isoforms is initiated at one of the three promoters, giving rise to transcripts starting either exon 1A, exon 1B or exon 1C. In addition, the small sequences of insertion/ deletion variation, especially seen around exon 6, together with short/long length variation of 3 0 -UTR, produces in total 11 mRNA isoforms. These isoforms are known to have different ability to stimulate production of IFNa and IFNb, and different expression pattern. Transcripts initiated at exon 1A and exon 1B are constitutively expressed in pDCs and B cells, whereas transcripts bearing exon 1C are inducible by type I IFNs. 70, 87 Graham et al. demonstrated that individuals who are homozygous for the rs2004640 G allele expressed IRF5 isoforms containing exon 1A and exon 1C, but not exon 1B. In contrast, individuals with the rs2004640T allele expressed transcripts containing exon 1B as well as other transcripts containing exons 1A and 1C. These results implied that rs2004640T represents a strong genetic risk factor for SLE probably through the influence on exon 1B splicing. 87 However, since exons 1A, 1B and 1C constitute 5 0 -UTR, the function of these different isoforms needs to be elucidated. Recent paper suggested that the translation efficiency of the isoform containing exon 1B is low, making the interpretation of the molecular mechanisms difficult. 88 Search for the causative polymorphism in IRF5 Sigurdsson et al. 64 and Graham et al. 87 focused on a limited number of SNPs already deposited in the database. In order to gain further insight into the molecular mechanism of association, several groups of investigators, including our own, have started to resequence the entire IRF5 genome to identify the polymorphism that plays a causative role.
In an entirely different research project, Cheung et al. carried out genome-wide testing of the 1 million HapMap phase I variants for association with gene expression in Epstein-Barr virus (EBV)-transformed B cells. 89, 90 They found 10 significant markers spanning 90 kb of chromosome 7 where IRF5 gene is located. Among them, rs2280714 was identified as the strongest cis-acting determinant of IRF5 expression. This finding led us to ask whether elevated expression marked by rs2280714 is associated with the risk to SLE. Given that rs2280714 is well downstream of IRF5 (B5 kb downstream of IRF5 3 0 -UTR), and that its position is not even in a recognizable regulatory region, we hypothesized that there may be additional genetic variation in tight linkage disequilibrium (LD) with rs2280714 that controls the expression phenotype.
In order to more fully characterize genetic variation in IRF5, we sequenced the exons, introns and 5 0 flanking region up to 1 kb. 91 Most of the subjects were Caucasians. In total, 52 variants were observed, of which 20 were previously identified. Although none of the identified SNPs was a missense variation with a minor allele frequency 41%, we observed a 30 bp insertion/deletion (indel) of exon 6, which lead to 10 amino acid inframe indel. Newly identified variants were genotyped in the HapMap CEU samples, and by combining the data with the publicly available SNP genotype data from the International HapMap Project, we were able to select 25 tagSNPs based on r 2 40.8 and minor allele frequency 41% threshold. 92 Then we tested association of tagSNPs with disease risk in 555 trio and sib-pair SLE families from the United States and the United Kingdom. After extensive conditional logistic regression analysis (http:// pngu.mgh.harvard.edu/purcell//whap/), SNPs in three distinct regions of IRF5 gene came out as an independent risk factor for SLE. One was the region where rs2004640 is located, and rs2004640T allele that influences exon 1B splicing itself was the most likely causal variation. The second region was within 3 0 -UTR represented by rs10954213. The third region was represented by rs2070197 SNP, which was B1.6 kb downstream of exon 6 indel variation.
91
IRF5 polyadenylation (poly A) site SNP was the second genetic risk factor for SLE in Caucasians Among four SNPs in 3 0 -UTR region of IRF5, we found two SNPs (rs10954213 and rs10954214) that were in strong LD with rs2280714. Since rs2280714 was shown to be associated with high gene expression of IRF5, 89, 90 we next examined the correlation between these 3 0 -UTR SNPs and IRF5 expression level. The mRNA expression data of 210 HapMap samples (CEU, CHB, JAP and YRI populations) collected at Sanger Institute (http:// www.sanger.ac.uk/humgen/genevar/) and mRNA expression data set of 233 CEPH samples 89 both revealed that rs10954213 SNP was most strongly associated with gene expression among all the tagSNPs encompassing the entire IRF5 gene. rs10954213 A allele was significantly correlated with higher mRNA expression. Therefore, rs10954213 was concluded to be the best predictor of IRF5 expression, and previously detected rs2280714 was considered to be a proxy. However, expression analysis using whole blood cell of SLE cases provided evidence that rs2004640 also contributes to high level of IRF5 expression to some extent.
91 Figure 1 Three potentially functional IRF5 variations associated with SLE in Caucasians. There are three potentially functional variations in IRF5 that are associated with SLE in Caucasians: (1) exon 1b splicing donor site, (2) 30 amino acid indel of exon 6 PEST domain and (3) polyadenylation site in 3 0 -UTR. These three variations define the risk haplotype 1 and protective haplotype 4 and 5 for SLE. Association of haplotypes with SLE were examined by meta-analysis using 555 complete trio pedigrees from United States and United Kingdom, and total 2188 cases and 3596 controls from United States, United Kingdom and Sweden. 91 
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If an SNP allele that is best correlated with high gene expression is also associated with disease risk, it makes perfect sense. That was indeed the case with rs10954213 in Caucasians. Our case-control study in the Caucasians revealed that the A allele frequency was 67.2% in SLE and 61.2% in control (P ¼ 9.1 Â 10
À5
). Next we examined the function of rs10954213 to explain how SNP affects the gene expression. By looking at the sequence, we realized that rs10954213 was located within an evolutionarily conserved poly A signal in the 3 0 -UTR region of IRF5. The substitution of G for A was predicted to disrupt a poly A þ signal sequence (AAUAAA4AAUGAA). The AAUAAA motif in 3 0 -UTR is well known to serve as a binding site for CPSF (cleavage and polyadenylation specificity factor). During RNA polymerase II transcription, CPSF binds to the AAUAAA sequence, and together with cleavage stimulation factors, forms a complex that cuts the mRNA strand 10-30 bp downstream of the poly A þ signal, and initiates polyadenylation of the transcripts. [93] [94] [95] Therefore, we hypothesized that rs10954213 might influence polyadenylation and result in different length and stability of the IRF5 mRNA. Specifically, we hypothesized that A allele of rs10954213 might allow efficient polyadenylation at B12 bp downstream of AAUAAA motif, while the G allele favors the use of a distal poly A þ site 648 bp downstream.
To test this hypothesis, we carried out northern blotting and TaqMan quantitative PCR assay using IRF5 mRNA from EB-transformed cell lines and PBMC of known genotype at rs10954213. As expected, cells homozygous for the A allele at rs10954213, carrying the wild-type AAUAAA on both alleles, expressed mainly a short version of IRF5 mRNAs (termed 'short'). In contrast, cells homozygous for the G allele (AAUGAA) expressed almost exclusively a longer mRNA (termed 'long') that utilized the second downstream poly A þ site 91 ( Figure 1 ). This observation was also confirmed by Cunninghame Graham et al. 96 using Affymetrix expression array. In fact, IRF5 mRNAs corresponding 'short' and 'long' were already deposited in Genbank database.
To experimentally address the functional difference, we cloned the two versions of IRF5 3 0 -UTR, short and long, into the downstream of the coding region of rabbit b-globin, and transfected 293 'Tet-off' kidney cells with expression plasmids. After suppression of new transcription by Doxycycline, we quantified the amount of mRNA at the different time point by northern blotting. The long mRNAs had about three times shorter half-life than short mRNAs. Estimated half-lives of short and long mRNA were 342788 and 125721 min, respectively. 91 Furthermore, we confirmed that cells carrying rs10954213 A/A genotype at poly A þ site (mainly express short mRNA) showed about fivefold higher level of IRF5 protein than cells carrying rs10954213 G/G genotype (almost exclusively express long mRNA) by western blotting. 91 These observations indicated that rs10954213 that influences IRF5 polyadenylation is the second causal variation for the genetic risk to SLE in Caucasians. The risk allele produces short and relatively stable mRNA, and leads to higher level of mRNA and protein expression, which may result in excessive production of type I IFN production.
Exon 6 indel variation was the third genetic risk factor for SLE in Caucasians
By sequencing IRF5 genome, we observed 30 bp (10 amino acid) exon 6 indel variation (Figure 1 ). The exon 6 indel was located in a proline-, glutamic acid-, serineand threonine-rich (PEST) domain of IRF5, a motif previously implicated in protein stability and function in the IRF family of proteins. 97 As described above, we observed that rs2070197 confers the third genetic risk of IRF5 for SLE, but we could not see any relevant functional importance in this as well as any other SNPs in the neighboring region. Therefore, we re-analyzed the genetic data based on the hypothesis that rs2070197 is tagging other functional variation; most likely exon 6 indel because of its potential function and relatively close location to it (B1.6 kb upstream). Finally by TDT analysis in 555 trio and sib-pair SLE families from the United States and the United Kingdom, we observed association of exon 6 insertion with higher genetic risk for SLE only when conditioned on the exon 1B splicing SNP (rs2004640) and poly A site SNP (rs10954213) (337:294
). The rs2070197 was shown to be a great predictor of exon 6 indel variation in Caucasians, because it tags particular haplotype composed of three SLE risk variations (rs2004640, exon 6 indel, rs1095213) 91 ( Figure 1) .
The function of IRF5 exon 6 indel is putative and yet under investigation. In addition to exon 6 indel, alternative splice acceptor site variations for exon 6 termed SS1 and SS2 91 that cause 48 bp indel at the beginning of exon 6 influence transactivation of downstream genes. 70, 76, 79 This variation might be worth taking into consideration in the future study. The conditional logistic regression analysis that includes these three variations revealed that there is no additional SNP to explain the full signal of IRF5 association to SLE.
Haplotype analysis of three SLE risk variations in IRF5 We found three putative functional common variations of IRF5, which affect isoform structure and/or expression: (1) an SNP at the exon 1B splicing donor site (rs2004640), producing transcripts containing exon 1B, (2) a 30 bp inframe indel of exon 6 that alters a PEST domain region, (3) an SNP in a conserved poly A signal (rs10954213) associated with altered length of the IRF5 3 0 -UTR, and altered transcript levels 91 ( Figure 1 ). Although each variation was independently associated with risk to SLE to some extent, haplotype analysis in a large family collection with 555 trio pedigrees from United States, United Kingdom and a case-control sample totaling 2188 case and 3596 control chromosomes from United States, United Kingdom and Sweden showed that distinct combinations of these three variants define three different levels of risk for SLE. Among the five common haplotypes defined, only haplotype 1 that has the ability to express exon 1B isoforms (due to rs2004640), carries the exon 6 insertion and is expressed at high levels due to the poly A þ variant was strongly associated with risk of SLE, appearing on 19.0% of SLE chromosomes compared to 11.9% of control chromosomes (OR ¼ 1.78, 95%CI: 1.57-2.02, P ¼ 1.4 Â 10 À19 ). Haplotypes 2 and 3, which carry only 2 of the 3 risk-associated functional alleles, were average risk to SLE with no statistical significance (OR ¼ 1.09 and 0.95, respectively). Haplotypes 4 and 5, which carry only 1 of the 3 risk-associated functional alleles, and notably they both lack exon 1B isoform, showed B25% reduction in risk with a protective effect for SLE (OR ¼ 0.76 for both haplotypes, P ¼ 5.0 Â 10 À8 and P ¼ 2.8 Â 10
À5
, respectively) 91 ( Figure 1) . Recently, these data were replicated by independent study in Spanish, Argentine and German populations. 88 Type I IFN system in human SLE Figure 2 illustrates a model on the aberrant induction of type I IFN pathway in human SLE. Here we focus on how IRF5 and IFN signature stories can fit in the currently proposed model of SLE pathogenesis. 16, 98, 99 The specific chromatin components such as ssRNA and dsDNA, either from infected viruses or internalized IC from apoptotic cell, are carried to endosome with a help of Fcg receptors and trigger TLR7/8 and TLR9 signaling in pDCs, where IRF5 is either highly expressed and/or functionally potent because of gene polymorphisms. Activated IRF5 translocates to nucleus and stimulates transcription of various inflammatory cytokines including type I IFNs. The unabated production of type I IFN further induces IFN-responsive genes termed 'IFN signature' in various types of immune cells and leads to two key clinical features characteristic to SLE: (1) autoantibody production (IC formation) and (2) inflammation and damage to systemic organs.
Firstly, upregulated production of type I IFN induces the generation of mature DCs that capture nuclear antigens and presents them to CD4 þ T cells. Activated T cells, in turn, stimulate autoreactive B cells to produce autoantibodies. This results in the breakdown of tolerance to nuclear antigens, autoantibody secretion and IC formation characteristic of SLE, and also provides amplification loop for further stimulation of pDCs to produce greater quantities of type I IFNs. Alternatively, since TLR7/8/9 and IRF5 are also expressed in B cells, co-ligation of the B-cell receptor and TLR by ICs can directly stimulate development of autoreactive B cell to produce autoantibodies, where abnormal function of IRF5 allows B-cell tolerance breakdown against autoantigens. Polymorphisms in HLA-DRB1 100 or reductionof-function polymorphisms in the B cell-inhibitory receptor, FCGR2B, 59, 61 are likely to be involved in an additive or epistatic manner in these processes.
Secondly, upregulated production of type I IFN affects inflammatory cytokine-producing cells such as macrophage, NK cells and cytotoxic CD8 þ T cells, to mediate cytotoxic effector function. Activation of these cells by type I IFN results in tissue damage at the site of the cell encounter with pathogens. As shown in the IFN signature of serum protein in SLE, high expression of chemokines may disturb the normal trafficking and chemotaxis of these cytotoxic effector cells to the correct location of the body and contribute to the broader range of inflammation and systemic tissue damage featured in SLE. The tissue damage also yields large numbers of nucleosomes that can be captured by pDCs and mature DCs, further amplifying the autoreactive process.
The first trigger may be small increase in the type I IFN levels; however, once an autoreactive process starts, such Genetics of type I IFN in human SLE C Kyogoku and N Tsuchiya a self-activating system may exaggerate the strength of type I IFN signaling activity in genetically predisposed individuals and may lead to the development of SLE (Figure 2 ).
Future perspective
Type I IFN pathway is triggered as a normal event of immune system to protect our body from pathogens. However in SLE, genetic alterations in this pathway appears to lead to the sustained overproduction of type I IFN, which activates autoantigen-presenting cells (DCs), autoreactive T cells, autoreactive B cells and cytotoxic effecter cells. Because most of the autoimmune responses featured in SLE, such as peripheral tolerance breakdown, nuclear autoantibody production, IC formation and systemic tissue damage, can be explained at least in part by impaired type I IFN system, it seems likely that type I IFN plays a major role in the pathogenesis.
IRF5 is the first and so far the only gene in the type I IFN pathway whose genetic variations were confirmed to be associated with human SLE by large-scale association studies. However, most of the published studies analyzed Caucasian populations. In view of substantial difference in the allele frequencies and haplotype structure among populations, it is important to examine Asian and African populations for the association of IRF5 with SLE. A recent report from Korea replicated the association of rs2004640 with SLE. 101 We used an ethnic collection from the Human Genome Diversity Panel (HGDP) 102 to gain information on the frequency of IRF5 alleles in world populations. Importantly, the high-risk haplotype (haplotype 1) was rare/absent, whereas the protective haplotypes (haplotypes 4 and 5) were more frequent, in the East Asian and African populations. 91 Indeed, recent association studies including our own revealed substantial difference in the haplotype structure between Asian and Caucasian populations (submitted for publication). It would be of particular interest to see whether the same genetic effects of exon 6 indel and poly A site SNP are observed, and whether other polymorphisms are involved, in populations other than the Caucasians.
As represented by our study on IRF5 as well as other numerous studies, disease-associated gene variations are often related to gene expression and isoform structures. Relevant variation in a gene is not necessarily one, but could be several, and the haplotype composed of multiple variations may confer full genetic risk to disease. Different levels of risk for disease in individuals can be defined by the haplotypes within a gene, as well as genetic epitasis between multiple susceptible genes. Taking these into consideration will help us search for new gene variations associated with disease risk and adequately understand the data from genetic association study.
It is also important to search for genetic variations in other genes that control type I IFN production or are involved in downstream signaling pathway. There is evidence from a mouse study that loss of IRF4-binding protein leads to the spontaneous development of a systemic autoimmune disorder characterized by the accumulation of effector/memory T cells and IgG þ B cells, autoantibody production and glomerulonephritis similar to human SLE. 103 As IRF4 is known to compete with IRF5, thus serving as negative regulator of TLR signaling, attenuated function of IRF4 may lead to increased function of IRF5. A recently reported human study showed that promoter SNP in IRF3 was protectively associated with development of SLE in Japanese. 104 This SNP was associated with decreased mRNA expression of IRF3, suggesting that decreased transactivation of IRF3 may be related to risk for SLE.
Lastly, it is important to investigate the molecular mechanisms that link the polymorphisms and the development of SLE. The functional alteration caused by a common genetic variation is, in itself, generally subtle and should be considered in the context of other genetic variations and environmental stimuli. Also, there is a certain limit of using primary cells from patients for experiment. Recently, more sensitive detection systems are developed and resources of human cell lines with annotated information by genome projects are available. Taking full advantage of these resources, we need to take a further step into the great challenge to delineate genegene interactions and gene-environment interactions in the development of lupus and other autoimmune diseases.
